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ARTICLE
Computational Opioid Prescribing: A Novel Application of
Clinical Pharmacokinetics
Oscar A. Linares and Annemarie L. Linares
ABSTRACT
We implemented a pharmacokinetics-based mathematical modeling technique using algebra to assist pre-
scribers with point-of-care opioid dosing. We call this technique computational opioid prescribing (COP). Be-
cause population pharmacokinetic parameter values are needed to estimate drug dosing regimen designs for
individual patients using COP, and those values are not readily available to prescribers because they exist scat-
tered in the vast pharmacology literature, we estimated the population pharmacokinetic parameter values for 12
commonly prescribed opioids from various sources using the bootstrap resampling technique. Our results show
that opioid dosing regimen design, evaluation, and modification is feasible using COP. We conclude that COP
is a new technique for the quantitative assessment of opioid dosing regimen design evaluation and adjustment,
which may help prescribers to manage acute and chronic pain at the point-of-care. Potential benefits include
opioid dose optimization and minimization of adverse opioid drug events, leading to potential improvement in
patient treatment outcomes and safety.
KEYWORDS clinical pharmacokinetics, dose optimization, dose regimen design, dosing, opioids, pharma-
cokinetics
INTRODUCTION
The expected clinical outcome measure of interven-
tional opioid pharmacotherapy for the treatment of
acute and chronic pain is analgesia. However, stud-
ies indicate that many patients in pain are prescribed
inadequate doses of opioid medications to relieve
their pain (1–5). Multiple barriers to the adequate
treatment of pain have been identified (6–9), but ra-
tional opioid dosing founded on pharmacokinetics-
based opioid dosing regimens for individual pa-
tients has not been adequately addressed. To date,
clinical pharmacokinetics-based opioid dosing reg-
imen design and adjustment in acute and chronic
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pain management has been the subject of a lim-
ited number of publications (10, 11), although
pharmacokinetics-based anesthetic opioid dosing is
routine (12–14).
Opioid maximum concentrations (Cmax) and min-
imum concentrations (Cmin) may correspond to their
minimum toxic concentrations (MTCs) and mini-
mum effective concentrations (MECs). For exam-
ple, the therapeutic range of morphine for analge-
sia is reported to be between 9.3 and 80 ng/mL,
MEC range 9.3 to 23 ng/mL (15). This range im-
plies that concentrations above 80 ng/mL are more
likely to be associated with toxicity and concentra-
tions below 9.3 ng/mL are more likely to produce lit-
tle or no analgesic effect. Therefore, in the course of
pain management with morphine, it is desirable that
a dosage regimen for morphine produce plasma mor-
phine concentrations within its therapeutic range.
The goal of the design of an opioid dosing regimen
is thus to achieve predicted plasma opioid concen-
trations within or at the boundaries of targeted Cmax
and Cmin values or a desired target concentrations
(Ctarget).
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This contribution introduces a novel application of
clinical pharmacokinetics for opioid dosing regimen
design and dose adjustment termed computational
opioid prescribing (COP). A major aim of COP is
the design of individualized opioid dosage regimens
for patients in order to administer opioid doses based
on their predicted plasma concentrations within pre-
set Cmax and Cmin values or steady-state concentra-
tion (Css)a n dCtarget for multiple dosing regimens. Be-
cause pharmacokinetic parameter values for COP are
not readily available, but rather exist scattered about
in the vast pharmacology literature, we culled a large
number of studies and applied the bootstrap resam-
pling technique to compute opioid population phar-
macokineticparameterestimatesfor12opioidsasref-
erence for using COP.
METHODS
Opioid Population Pharmacokinetic
Parameter Estimation
Population pharmacokinetic parameter values are of-
ten used to estimate drug dosing regimen designs for
individual patients in whom patient-specific param-
eter values are not available (16,17); however, opi-
oid pharmacokinetic parameter values are scattered
about in the vast pharmacology literature. Therefore,
we culled a large number of studies using references
(18–21), the reference lists therein, the reference
lists of the references therein, and literature searches
using PubMed.gov and Scholar.Google.com with
search terms entered: opioids pharmacokinetics, opi-
oids pharmacodynamics, and the latter terms, substi-
tuting the word opioids for each of the 12 individual
opioids studied, so as to obtain pharmacokinetic pa-
rameter values for the following 12 opioids: (1) mor-
phine, (2) tramadol, (3) codeine, (4) meperidine, (5),
hydrocodone, (6) oxycodone immediate-release (IR),
(7) oxycodone controlled-release (CR), (8) hydro-
morphone, (9) oxymorphone, (10) methadone, (11)
fentanyl, and (12) buprenorphine. The inclusion cri-
teria were human studies, articles published in the
English language, any of the aforementioned 12 opi-
oid drugs administered via intravenous, oral, or in-
tramuscular routes, doses or range stating doses of
the opiate(s) measured in plasma, opiate(s) concen-
tration levels given in numerical or graphic form, and
noncompartmental or compartmental pharmacoki-
netic parameters estimated. Necrokinetics data were
exlcuded.
Since COP assumes a one-compartment model
(see below), we pooled the reported values of the
following four primary pharmacokinetic parameters
of disposition for the one-compartment model: the
half-life (t1/2), the first-order elimination rate constant
(ke), the apparent volume of distribution (Vd), and
the systemic clearance rate (Cl). These pharmacoki-
netic parameters are required to compute an appro-
priate opioid dose and dosing interval using the one-
compartment model.
The large number of studies analyzed allowed a
statistical approach in which the mean values from
each study provided single data points (independent
samples). When mean group values were not re-
ported, the published experimental study data (22)
was used to derive the primary pharmacokinetic pa-
rameter or parameters using modeling (23). All stud-
ies, despite their probable variable reliability, were
accorded equal weight. Values for opioid bioavail-
ability (F) were obtained from references (18–21),
the references therein, or literature search. Values for
the first-order absorption constant (ka) were obtained
fromreferences(18–21),thereferencestherein,orlit-
erature search, but, when values were not available,
they were computed using the equation:
ka =
k2
e · eTmax
ke · eTmax − 1
. [1]
Opioid population pharmacokinetic parameter es-
timation using the bootstrap (see below) was not per-
formed for F or ka values.
Opioid population pharmacokinetic parameter es-
timation was performed using the bootstrap resam-
pling technique (24–27). The idea underpinning the
bootstrap is to repeatedly sample with replacement
(bootstrap samples) from the samples available, and
use the bootstrap samples to compute the sampling
distribution of the statistics of interest. Bootstrap
samples look pretty much like drawing a new sample
and provide good estimates of what would happen if
we really were able to draw new fresh samples from
the population of interest.
Simplified Clinical Pharmacokinetic Equations
for COP
A major aim of COP is to allow rapid, at the point-
of-care, computations to be made of opioid clinical
pharmacokinetic parameter values using pencil and
paper or a calculator (28,29).
Equation 2 defines the target average steady-state
plasma opioid concentration (Css
ave) based on the min-
imum (Css
min) and the maximum (Css
max) steady-state
opioid therapeutic range concentrations:
C
ss
ave =
Css
max − Css
min
ln

Css
max
Css
min
 [2]
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Equation 3 defines the opioid dosing rate (dose/τ),
where τ represents the dosing interval necessary to
achieve Css
ave. This calculation requires knowing the
opioids F and Cl:
Dose

τ =
Css
ave · Cl
F
[3]
Equation 4 gives the rate of decline of plasma opi-
oid concentration from Css
max to Css
min:
C
ss
min = C
ss
max · e
−keτmax [4]
This rate is governed by the t1/2 or ke because
ke = 0.693/t1/2 and vice-versa. Equation 4 can be
solved for τmax, giving
τmax =
ln

Css
max
Css
min

ke
. [5]
The opioid maintenance dose (DM) is given by
DM(maintenancedose) =
Ctarget · Cl
F
[6]
where Ctarget is the targeted plasma opioid concen-
tration. In some cases, administration of a loading
dose (DL) may be necessary:
DL(loadingdose) =
Cp · V d
F
. [7]
where Cp represents the plasma opioid concentration.
For multiple dosing, the accumulation ratio (AR),
which represents the ratio of opioid in the body at
steady-state relative to the amount of opioid in the
body after a single dose, is given by
AR =
1
1 − e−keτ
∼ =
τ
t1/2
. [8]
Hence,themaximum(Css
max)orpeakplasmaopioid
concentration is given by
C
ss
max(peak) =
F · D
V d
× AR, [9]
and the minimum (Css
min) or trough plasma opioid
concentration by
C
ss
min(trough) = C
ss
max · e
−keτ × AR. [10]
The average steady-state plasma opioid concentra-
tion (Equation 1) can also be obtained using
C
ss
ave =
F ·

D
τ

Cl
. [11]
At any time (T), Cp is given by
Cp(T) = C
ss
max · e
−keT. [12]
Opioid Dosing Regimen Design Using COP
A major aim of COP is the design of an opioid
dosage regimen that achieves predicted plasma opi-
oid concentrations within a safe and effective range.
COP assumes that opioid clinical pharmacokinetics
can be reasonably approximated by a linear open
one-compartment model with first-order absorption
and first-order elimination (Figure (1)). This model
has been shown to account for the pharmacokinetics
of many important drugs (30), including the opioid
analgesics (21). In certain circumstances, however, it
may be associated with significant error in the calcu-
lation of a drug’s absorption rate constant, ka, such as
when ka = ke.
The required data to design an opioid dosage
regimen using COP is information about the phar-
macokinetics of the opioid, the values reported in
Table 1), and the opioid’s therapeutic range (31).
Pharmacokinetic parameter values calculated using
COP can be expected to have an inter-individual vari-
ation of about 25%, which may be clinically accept-
able.
However, the following are assumptions and lim-
itations of using the one-compartment model (32):
(1) it is assumed that the pharmacokinetic parame-
ters remain constant during the course of treatment;
(2) changes in renal and/or hepatic function may pro-
long the excretion of the fraction of opioid excreted
unchanged in the urine, or metabolized by the liver;
(3)congestiveheartfailure(CHF)andmyocardialin-
farction (MI) may cause reduction in blood flow, re-
sulting in reduced volume of distribution and clear-
ance, thereby prolonging opioid elimination.
Qualifications for using the one-compartment
model when a theoretically correct model is multi-
compartmental are as follows (32,33): (1) the major-
ity of the opioid distributes to rapidly perfused tissues
and circulating fluids in the central compartment;
and (2) although opioid distributes to tissues char-
acterized by an open two-compartment model, since
the equations are based on a one-compartment
model, they can be applied to the open two-
compartment model if instead of ke, the terminal rate
constant, β, of the biexponential curve characteriz-
ingtheopentwo-compartmentmodelisusedinstead,
and instead of the one-compartment model apparent
volume of distribution, Vd, the volume of the central
compartment of the two-compartment model, Vc,i s
used.
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FIGURE 1 One-compartment models. The intravascular administration model
(left panel) is characterized by a single sampled compartment into which a dose of
drug is administered. The triangle cuts into the sampled compartment. In these
models, DB represents the mass of drug in the body, Vd is the apparent volume
of distribution of drug, and C represents the drug concentration, equal to D/Vd.
ke represents the first-order elimination rate constant (h−1). Drug is eliminated in
the urine unchanged and in metabolite form. In the extravascular administration
model(rightpanel),adoseofdrugisadministeredintoacompartmentfromwhich
the drug is transferred into the body via the gastrointestinal tract. F represents the
drug’s bioavailability. ka is the first-order absorption rate constant. The steady-
state plasma concentration of opioid over time for oral dosing is independent of
ka,s ot h ep a t hf r o mDGI to DB equals Dose × F.
RESULTS
Table 1) presents the population pharmacokinetic
parameter estimates of the four primary pharma-
cokinetic parameters of disposition for the one-
compartment model for the 12 opioids considered
in this study. The fractional values for oral admin-
istration (unless otherwise indicated) of F for each
of the opioids studied were as follows: morphine av-
eraged 0.38 with a range of 0.15 to 0.64; tramadol
was 0.73 males and 0.79 in females; codeine was 0.50;
meperidine had a range of 0.40 to 0.60 with an aver-
age of 0.50; hydrocodone was 0.80; oxycodone IR had a
range of 0.60 to 0.87 with an average of 0.74, which
was similar for oxycodone CR; hydromorphone had a
range of 0.52 to 0.58 with an average of 0.55; oxy-
morphone was 0.10; methadone was 0.80 with a range
of 0.10 to 0.90; fentanyl was 0.33 for the oral prepa-
ration, 0.50 for the buccal, and 0.92 for the patch;
and buprenorphine averaged 0.63 with a range of
0.50 to 0.75.
The ka values of each of the opioids studied were
morphine 15.6 h−1; tramadol 2.6 h−1; codeine 15.6 h−1;
meperidine 4.8 h−1; hydrocodone 2.8 h−1; oxycodone IR
3.5 h−1; oxycodone CR was 0.42 min−1 (first-phase re-
lease) and 3.2 h−1 (second-phase release); hydromor-
phone 3.1 h−1; oxymorphone 2.3 h−1; methadone 0.58
h−1; fentanyl 2.9 h−1;a n dbuprenorphine 0.52 h−1.
In each of the following subsections, results using
COP for opioid dosage regimen design and evalua-
tion are demonstrated using morphine, because mor-
phineisregardedasthebenchmarkofanalgesics(34).
The last case study, a forensic result, uses oxycodone
IR. Morphine was used with the following pharma-
cokinetic characteristics (Table 1)): elimination half-
life (t1/2) 3.9 hours; elimination rate constant (ke)
0.318 h−1; apparent volume of distribution (Vd)4 . 5
L/kg; clearance rate (Cl) 1.43 L/h/kg; F equal to 1.0
for intravenous dosing; F equal to 0.40 for oral dos-
ing; and therapeutic range, 10 to 80 µg/L.
Intravenous (IV) Bolus Dosing
Calculation of dose size and dosing interval is per-
formed using the equations for maximum and mini-
mumplasmadruglevelsatsteadystate,Css
maxandCss
min,
respectively. This method is called the limited fluctu-
ation method or Css
max− Css
min method (32). This ap-
proach is used when, within a dosing interval, the
desired steady-state opioid plasma levels to achieve
do not exceed Cmax and do not undercut the desired
Cmin.
First, we estimate a target average steady-state
plasma morphine concentration (Css
ave)b a s e do nm o r -
phine’s therapeutic window. Equation 1 defines Css
ave
based on the minimum (Css
min) and maximum (Css
max)
Journal of Pain &amp; Palliative Care PharmacotherapyJournal of Pain & Palliative Care Pharmacotherapy 129
TABLE 1 Opioid Population Pharmacokinetic Parameter Estimates Using the Bootstrap
Opioids (N = 1000) t 1
2
(h) ke (h−1) Vd (L/kg) Cl (L/h/kg)
Morphine 3.9 ± 1.7 0.318 ± 0.126 4.5 ± 1.4 1.43 ± 0.69
(3.7, 4.0) (0.305, 0.329) (4.4, 4.6) (1.35, 1.52)
Tramadol 5.5 ± 0.7 0.132 ± 0.017 2.8 ± 0.1 0.37 ± 0.06
(5.4, 5.6) (0.127, 0.136) (2.7, 2.8) (0.3598, 0.3763)
Codeine 2.6 ± 0.8 0.377 ± 0.116 3.0 ± 0.3 1.23 ± 0.45
(2.5, 2.7) (0.3653, 0.3880) (2.9, 3.0) (1.21, 1.26)
Meperidine 3.5 ± 0.9 0.242 ± 0.061 4.0 ± 0.1 0.98 ± 0.27
(3.4, 3.6) (0.234, 0.251) (3.9, 4.0) (0.97, 1.00)
Hydrocodone 6.1 ± 1.5 0.141 ± 0.036 4.0 ± 0.4 0.61 ± 0.20
(6.0, 6.2) (0.135, 0.148) (3.9, 4.1) (0.5938, 0.6230)
Oxycodone IR 4.5 ± 0.9 0.174 ± 0.034 2.8 ± 0.5 0.42 ± 0.003
(4.4, 4.6) (0.167, 0.180) (2.7, 2.8) (0.41, 0.42)
Oxycodone CR
Phase I 33.5 ± 2.1 min 0.021 ± 0.001 min−1 2.8 ± 0.5 0.06 ± 0.01 L/min/kg
Phase II (33.34, 33.66) (0.0194, 0.0219) (2.7, 2.8) (0.055, 0.063)
4.6 ± 0.6 h 0.160 ± 0.022 h−1 2.8 ± 0.6 0.58 ± 0.08 L/h/kg
(4.5, 4.7) (0.156, 0.165) (2.7, 2.8) (0.57, 0.59)
Hydromorphone 6.0 ± 1.7 0.154 ± 0.045 3.0 ± 0.6 0.54 ± 0.22
(5.0, 6.1) (0.147, 0.161) (2.9, 3.1) (0.52, 0.55)
Oxymorphone 8.0 ± 2.3 0.115 ± 0.033 3.0 ± 0.6 0.40 ± 0.17
(7.8, 8.2) (0.109, 0.122) (2.9, 3.1) (0.39, 0.42)
Methadone 35 ± 11.7 0.029 ± 0.009 5.5 ± 0.89 0.19 ± 0.08
(34.6, 35.4) (0.0258, 0.0323) (5.4, 5.6) (0.18, 0.20)
Fentanyl 7.5 ± 2.6 0.144 ± 0.049 5.5 ± 1.4 1.32 ± 0.73
(7.3, 7.7) (0.137, 0.152) (5.4, 5.6) (1.29, 1.35)
Buprenorphine 33.5 ± 8.7 0.026 ± 0.007 3.8 ± 1.5 0.13 ± 0.07 0pt1,95.0pt
(33.2, 33.8) (0.023, 0.029) (3.7, 4.0) (0.12, 0.14)
∗Values are bootstrap (49) mean ± SD; values in parentheses are bootstrap bias-corrected and -accelerated (50) 95% confidence intervals.
†All values computed from pooled literature values reported in the literature (see Methods) using the bootstrap (51) with N = 1000.
steady-state morphine therapeutic window concen-
trations equal to 10 and 80 µg/L, respectively:
C
ss
ave =
Css
max − Css
min
ln

Css
max
Css
min
 =
80 − 10
ln

80
10

=
70
2.1
= 33.7µg/L. [13]
Note that 33.7 µg/L is slightly different than the
algebraic average of 35 µg/L because we have as-
sumed that morphine pharmacokinetics can be de-
scribed by a one-compartment model. Therefore, the
plasma concentration of morphine undergoes first-
order elimination corresponding to exponential de-
cline instead of simple linear disposition (35).
Next, we estimate the dosing rate (dose/τ), where
τ represents the dosing interval necessary to achieve
Css
ave. This calculation requires knowing F (equal to 1
for IV dosing) and Cl of morphine (Table 1)):
Dose

τ =
Css
ave · Cl
F
. [14]
In the United States, where the average male
weighs 86.6 kg (190.9 lbs) and the average female
weighs 74.4 kg (164.0 lbs) (36), the estimates of
morphine population Cl are 123.8 L/h for males and
106.4 L/h for females. For IV administration, mor-
phine’s F is equal to 1. Hence, for the average male,
Dose

τ = C
ss
ave · Cl
Dose

τ = 123.8L/hr × 33.7µg/L = 4172.1µg/hr
= 4.2mg/hr [15]
and for the average female,
Dose

τ = 106.4L/hr × 33.7µg/L = 3585.7µg/hr
= 3.6mg/hr. [16]
Now, we estimate the maximum dosing interval
τmax. The rate of decline of the plasma morphine con-
centration from Css
max to Css
min is governed by mor-
phine’s t1/2 or ke. So, we can estimate how long it
would take for the plasma morphine concentration to
decline from a maximum to a minimum level. Set-
ting morphine’s therapeutic window boundaries (10
to 80 µg/L) as the limits of Css
max and Css
min, the time
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it takes for the plasma morphine concentration to fall
from 80 to 10 µg/L can be estimated as follows:
C
ss
min = C
ss
max · e
−keτmax. [17]
This equation can be solved forτmax, giving:
τmax =
ln

Css
max
Css
min

ke
. [18]
Substituting for morphine’s ke in Equation 18
gives,
τmax =
ln

80
10

0.318
= 6.5h r . [19]
The τmax of 6.5 h means that the longest dosing in-
terval that may be selected for the patient’s dosing is
6.5hours.Afterthattime,morphinelevelswillfallbe-
low Css
min. Also, because morphine administration ev-
ery 6.5 hours is not practical, choose a τ from one of
the following practical dosing intervals: 2, 4, 6, 8, 12,
or 24 hours. For convenience, one might be tempted
to choose a longer τ, e.g., 8 hours, however, a prac-
tical τ cannot be greater than τmax if the desired out-
come is to maintain plasma morphine concentrations
between Css
maxandCss
max. In this case, a τ of 6 hours is a
good first choice.
Knowing the dosing interval and the dose rate
(Dose/τ), the maintenance dose (DM) for the average
male is given by:
DM = Dose Rate × DosingInterval =

Dose

τ

×τ= 4.2mg/hr × 6 = 25.2m g . [20]
A similar computation may be made to determine
DM for the average female. If the dose is not practi-
cal or the available strengths of the drug do not allow
administration of the calculated dose, the dose may
be rounded to the nearest practical number. For in-
stance, the above morphine dose may be rounded to
25 mg.
Case Study 1
The patient is a 55-year-old Caucasian man newly di-
agnosed with cancer of the prostate and metastases
to the spine with normal cardiac, hepatic, and renal
function. He is experiencing 10/10 back pain. The
nurse on duty caring for the patient informs the doc-
tor that the patient has not received morphine in the
past, so he is opioid na¨ ıve. The nurse is not comfort-
able administering intravenous morphine 25 mg ev-
ery 6 hours to the patient. The doctor searches the
literature and finds evidence that in cancer patients,
morphine levels at or above 20 µg/L are considered to
be analgesic in most patients (37). This value is about
60% of the plasma morphine concentration calcu-
lated using COP (Equation 13). Using COP, the doc-
tor simulates a morphine dosage regimen equal to 12
mg every 6 hours to assess the effect it would have on
morphine pharmacokinetics in this patient.
The doctor reestimates Css
ave to predict the new
plasma morphine concentration using the practical τ
of 6 hours and the intravenous morphine dose of 12
mg.
C
ss
ave =
F ·

Dose

τ

Cl
=
12,000µg/6hr
123.8L/hr
= 16.2µg/L[ 2 1 ]
The simulation predicts that cutting the morphine
dose to 12 mg would not achieve the evidence-based
steady-state analgesic plasma morphine concentra-
tion of 20 µg/L or more. The doctor performs an-
other simulation using an intravenous morphine dose
of 15 mg every 6 hours.
C
ss
ave =
15,000µg/6hr
123.8L/hr
= 20.2µg/L[ 2 2 ]
The selected dose now predicts a plasma mor-
phine concentration within the evidence-based anal-
gesic value. To estimate the Cmax and Cmin values with
the reduced dose regimen, first, the Cmax and Cmin af-
ter the first dose (C1st
maxand C1st
min, respectively) are esti-
mated. Then, using the accumulation ratio (AR), the
Css
max and Css
min values are computed as follows:
C
1st
max =
Dose
V d
=
15,000µg
4.5L/kg × 86.6kg
=
15,000µg
389.7L
= 38.5µg/L
C
1st
min = C
1st
max · e
−keτ = 38.5 × e
−0.318×6 = 5.7µg/L
AR =
1
1 − e−keτ =
1
1 − e−0.318×6 = 1.2 [23]
C
ss
max = C
1st
max · AR =38.5µg/L × 1.2 = 46.2µg/L
C
ss
min = C
1st
min · AR =5.7µg/L × 1.2 = 6.8µg/L
AR represents the ratio of opioid in the body at
steady-state relative to the amount of opioid in the
body after a single dose (35). Thus, a dosage regimen
of 15 mg intravenous morphine every 6 hours would
be expected to result inCss
min, Css
max,a n dCss
avevalues
of 6.8, 46.2, and 20.2 µg/L, respectively. These
results suggest that, due to fluctuations in plasma
morphine concentrations, the patient’s pain may be
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undertreated towards the latter third of the dosing
interval. COP indicates that special clinical attention
to the patient’s symptoms should be made at around
that time.
In some cases, administration of a loading dose
(DL) or starting dose (DS) may be necessary, partic-
ularly if the half-life of the opioid is long and/or rapid
achievement of therapeutic opioid concentrations is
important, e.g., in acute pain. In these cases, DL may
be calculated using the t1/2 by the following method:
DL =

1.44 · DM · t1/2
τ

=
1.44 × 25.2 × 3.9h r
6hr
= 23.4mg [24]
The calculated dose should be adjusted for admin-
istration based on available morphine strengths.
Extravascular (Oral) Dosing
The computation of dose and dosing interval af-
ter extravascular dosing (e.g., oral administration) is
slightly more complicated than after intravenous (IV)
bolus dosing because the absorption rate (ka)a n dF
are important factors, in addition to the other four
basic clinical pharmacokinetic parameters. Neverthe-
less, simplified clinical pharmacokinetic-based equa-
tions for COP allow easy calculation of oral dosage
regimen designs (see above) that do not require ka,
because it can be shown that the terminal equilib-
rium level under constant infusion equals the aver-
age blood level over time for the terminal steady-state
under multiple IV or oral dosing (38). Also, a sim-
plification which applies to opioids, is when the ka
is much faster than the ke. Under this condition, ka
maybeassumedtobeinstantaneousforpracticalpur-
poses. In general, if the ka is 5 to 7 times greater than
the ke, the absorption rate may be assumed to be in-
stantaneous. This circumstance is similar to the IV
bolus administration of opioid (39), but with F less
than 1 so that the equations for IV bolus dosing ap-
ply. Therefore, the equations used for IV bolus dosing
above can also be used to design extravascular (oral)
dosage regimens with reasonable accuracy.
Case Study 2
The patient is a 52-year-old African American
woman weighing 302 lbs (137 kg), and is 2 days post-
operative from right knee arthroplasty. She complains
of 8/10 pain. She requests oral pain medication. Us-
ing the opioid plasma target concentration method,
the doctor selects a target morphine plasma concen-
tration equal to half of its MTC, i.e., 40 µg/L. F is set
equal to its algebraic average, which is calculated as
(0.15+ 0.64)/2 = 0.40. Then, the morphine dose for
starting treatment (DS = DL) is calculated using the
following equation:
DS(startingdose) =
Ctarget · V d
F
=
40µg/L · 4.5L/kg · 137kg
0.40
= 61,650µg. [25]
Multiplying by 0.001 converts µg to mg, so the
starting dose equals 62 mg, which can be rounded
to 60 mg for administration.
The time to reach steady state for morphine is Tss
= 5 × t1/2 = 20 hours. By this time, it can be assumed
that morphine’s rate in = rate out. Thus, the morphine
maintenance dose to achieve a steady state in Tss is
given by
DM =
Ctarget · Cl
F
=

40µg/L × 1.43L/hr/kg × 137kg
0.40

×0.001 = 20mg/hrs. [26]
Now, selecting a dosing interval where τ = 6 hours
gives DM = 120 mg every 6 hours. This is the dose re-
quired to maintain a steady-state plasma concentra-
tion of morphine of 40 µg/L. We confirm the dose as
follows.
Compute the accumulation ratio using
AR = τ / t1/2 = 6/4 = 1.5, then
C
ss
max(peak)=
F · D
V d
· AR=
0.40 × 120,000µg
4.5L/kg×137kg
· 1.5
=78µg/L
C
ss
min(trough) =C
ss
max · e
−keτ · AR=78µg/L × e
−0.318×6
= 17µg/L[ 2 7 ]
C
ss
ave =
F ·

D
τ

Cl
=
0.40 × 20,000µg/6hr
1.43L/hr/kg × 137kg
=40.8µg/L
Thus, COP demonstrates that our oral morphine
dosage regimen design achieved the therapeutic goal
of maintaining a steady-state plasma morphine con-
centration of 40 µg/L. The calculated value is slightly
higher due to computer round off error. Moreover,
COP shows that plasma morphine fluctuations about
Css
ave remain close to the bounds of morphine’s thera-
peutic window for analgesia. However, towards the
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end of the dosing interval, the concentration falls
slightly below the evidence-based plasma morphine
concentration for analgesia of 20 µg/L. COP indi-
cates that an adjustment in the dosing interval can
be made if the patient complains of pain towards the
end of the dosing interval. For example, using Equa-
tions 12 or 17, at the 5th-hour into the 6th-hour
dosing interval, plasma morphine concentration is 24
µg/L, indicating that the patient needs to be followed
closely for symptoms of pain during the last hour of
the dosing interval when plasma morphine concen-
trations fall below the evidence-based analgesic con-
centration.
Constant Intravenous Infusion
To determine intravenous infusion rate we need only
determine the infusion rate constant (k0) and do not
need to compute τ. To determine a constant rate in-
travenous infusion of morphine, we estimate k0 based
on a desired morphine Ctarget to achieve, and its Cl,s o
that k0 = Ctarget · Cl. We chose a value for Ctarget within
morphine’s therapeutic window. If rapid achievement
of steady-state morphine concentration is desired, an
intravenous loading dose may be calculated using
Equation 7 or simply DL = Ctarget · Vd. For exam-
ple, an intravenous DL of morphine based on Ctarget
= 25 µg/L in an average-weight woman in the United
State equals 25 µg/L × 4.5 L/kg × 74.4 kg × 0.001 =
8m g .N o w ,k0 = 25 µg/L × 1.43 L/h/kg × 74.4 kg ×
0.001=3mg/h.Thus,administrationofDL produces
a plasma morphine concentration of about 24 µg/L
(not exact due to computer round-off error), which
is maintained by simultaneously starting a morphine
infusion at a rate of 3 mg/h.
Opioid Dosing Regimen Evaluation
Dosing regimen evaluation using COP applies to pa-
tients who present on a dosage regimen prescribed
by another prescriber or an emergency department
(ED) physician. The goal is to determine the ade-
quacy of the regimen to achieve evidence-based anal-
gesic plasma concentrations of opioid.
Case Study 3
A 38-year-old average weight man was seen in the
ED 24 hours ago and placed on an oral regimen of
10 mg morphine sulfate every 8 h for 7/10 back pain
secondary to a fall from a 6-foot ladder. He was in-
structed to follow-up with pain management on the
next day. He presented 24 hours later. On evaluation,
he reported taking medications as prescribed and a
moderate increase in pain which he rated 8/10. Lum-
bosacral, spine, and hip films in the ER were normal.
At the discharge dose and dosing interval, it would
take 20 hours to reach a steady-state plasma mor-
phine concentration of
C
ss
ave =
F ·

D
τ

Cl
=
0.40 × (10,000µg/8hr)
1.43L/hr/kg · 86.6kg
=
500
124
= 4.0µg/L[ 2 8 ]
Clearly, the patients dosage regimen is inadequate
to meet his analgesic needs, since only morphine lev-
els at or above 20 µg/L are considered to be analgesic
(15,37). Thus, a dosage adjustment, rather than an
extensive work-up, was indicated to manage this pa-
tients increasing pain.
Case Study 4
A petite 29-year-old woman weighing 110 lbs (50 kg)
fell from a chair and fractured her coccyx. She was
seen in the ED and started on oral morphine sulfate
20 mg every 4 hours. She presented for pain man-
agement within 24 hours. She reported increasing
pain. On direct questioning, she reported that when
she took the first dose of morphine, she felt relief
for about 15 minutes. The doctor performed a clini-
cal pharmacokinetics assessment to determine Css
max,
Css
min,a n dCss
ave as follows:
C
ss
max(peak) =
F · D
V d
· AR =
0.40 × 20,000µg
4.5L/kg × 50kg
× 1.0
= 36µg/L
C
ss
min(trough) = C
ss
max · e
−keτ · AR = 36µg/L×e
−0.381×4
×1.0 = 10µg/L [29]
C
ss
ave=
F ·

D

τ

Cl
=
0.40 × (20,000µg/4hr)
1.43L/hr/kg × 50kg
=
1000
72
= 28µg/L
The patient’s clinical pharmacokinetics profile
looks good, there is no evidence that she is receiving
too much morphine. Her results show that predicted
trough levels are at the lower end of the therapeutic
window.
To design an individualized dosage regimen based
on the patients response to the morphine, the doctor
predicts what her plasma concentration of morphine
would be 15 minutes after she takes a dose:
Ct(15) = C
ss
max · e
−keT · AR = 36µg/L × e
−0.318×0.25
×1.0 = 33µg/L. [30]
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Based on this computation, the doctor decides to
set Ctarget = 35 µg/L, which is the average value be-
tween Css
maxand Ct(30), to calculate a maintenance
dose:
DM =
Ctarget · Cl
F
=

35µg/L×1.43L/hr/kg×50kg
0.40

×0.001 = 6mg/hr. [31]
Since 24 mg every 6 hours is not practical, the
doctor selects a dose of 25 mg every 4 hours for the
patient. This dose will be associated with a Css
max =
44 µg/L and Css
min = 12 µg/L. One hour after a dose,
the plasma morphine concentration will be 32 µg/L.
By 1 hour and 15 minutes after a dose, plasma mor-
phine concentration will be 30 µg/L, but by 1
1
2 hours
it will have fallen to 28 µg/L.
The patient is seen for follow-up within 3 days. She
reports being pain free up for about 1
1
2 to 2 hours af-
ter taking a scheduled morphine dose. Thus, COP
predicts she requires a plasma morphine concentra-
tion ≥30 µg/L for pain relief. In addition, COP in-
dicates the patient will need a long-acting morphine
combinedwithrescuedosesofshort-actingmorphine
for adequate pain control.
Case Study 5
In the course of chronic pain management, if a pa-
tient with chronic pain dies and becomes a medical
examiners case, opioid levels obtained at autopsy can
be misinterpreted in determining cause of death (40).
In February 1999, a physician was charged with three
counts of murder alleged to result from lethal oxy-
codone doses (41). In one case, the victim died in a
motor vehicle accident, but at autopsy was found to
have an oxycodone blood level of 21,900 µg/L. As-
suming no significant postmortem redistribution of
oxycodone, using the oxycodone IR values in Table
1) with F = 0.74,
DM =
Ctarget · Cl
F
=
21,900µg/L × 0.42L/hr/kg × 74.4kg
0.74
= 925µg/hr, [32]
which for dosing intervals equal to every 4 and 6
hours, the corresponding administered doses of oxy-
codone IR would equal 3700 µg( 4m g )a n d5 5 0 0µg
(6 mg) every 4 or 6 hours, respectively. COP indicates
that an oxycodone blood level of 21,900 µg/L can be
associated with low-dose oxycodone IR administra-
tion, not lethal doses, as implied by the County Med-
ical Examiner in this case.
In this case, the patient’s boyfriend was driving the
car. The patient died in the motor vehicle accident of
a hangman’s fracture of the cervical spine, open skull
fracture, and severe internal injuries. Because she had
opioid drugs in her system, the County Medical Ex-
aminer determined that she died of an opioid over-
dose instead of the obvious lethal injuries sustained
in the motor vehicle accident (42).
DISCUSSION
Prescribers, in general, may be concerned that the
mathematics of pharmacokinetics precludes practical
application at the point-of-care. This opinion may be
rooted in an assumption that if a drug is not work-
ing, more should be given or, conversely, if it is pro-
ducing toxicity, less should be given. This empirical
approach, although not without merit, means that
learning how to use any opioid safely will entail a long
an inefficient period of trial and error. Indeed, we
are presently witnessing a global epidemic of opioid-
related deaths due to overdose (43,44). These opioid-
related increases in deaths may be due, in part, to
an empirical approach to opioid dosing regimen de-
sign and modification. COP may therefore constitute
a potentially important tool for opioid dosing regi-
men design and adjustment, which may lead to the
prevention of adverse opioid drug effects, including
death from iatrogenic overdose.
For example, in U.S. v. Hurwitz (45), an expert
witness for the government testified that high-dose
opioid therapy typically involved doses of the equiva-
lent of approximately 195 mg of morphine a day. Our
results indicate that the average man would receive
about 100 mg of morphine per day. The doses pre-
scribed by Hurwitz, however, vastly exceeded those
quantities. Hurwitz often wrote prescriptions calling
for a patient to take 30 80-mg OxyContin tablets per
day, which is the equivalent of a total daily dose of
2,400,000 µg. Using COP, such a dose would be as-
sociated with a plasma oxycodone concentration of
about 9898 µg/L. Plasma oxycodone concentration
range from 600 to 5000 µg/L is associated with in-
duction of coma and death (46).
A potential limitation of the current implemen-
tation of COP is that it is not integrated into an
opioid therapeutic drug monitoring (TDM) phar-
macovigilance program, TDM is not routinely used
in everyday clinical practice when prescribing opi-
oids, as its role in opioid management is not yet
well defined. Nevertheless, indications for TDM are
relevant for all drugs, with or without validated
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therapeutic windows (47). When literature references
on therapeutic ranges are not available, targeted con-
centration ranges should be plasma concentrations
that have been observed at therapeutic doses of the
drug.
We cannot expect that measured plasma opioid
drug concentrations will be identical to opioid drug
concentration predicted using COP, because there is
always inter- and intraindividual variation, measure-
ment error, and model misspecification error. Mis-
specification error is due to representing the body as
a single compartment. Thus, the difference between
the patient and the model (interindividual variabil-
ity), and the difference between the patient’s “true”
value, if it could be known, and the measured con-
centration (residual intraindividual variability) will
account for the differences in the COP predictions
relative to the measured drug concentration.
The authors of this contribution have made every
effort to ensure the accuracy of the information pro-
vided at the time of its composition. Nevertheless, it
remains the responsibility of every prescriber to eval-
uate the appropriateness of a particular result in the
context of the actual clinical situation and to con-
sider any new developments in the field. Although
the authors have been careful to make COP adhere
to current standards and responsible literature, the
authors recommend prescribers consult appropriate
informational sources when prescribing new or unfa-
miliar opioid drugs.
COP was designed as a clinical-decision support
tool for prescribers at the point-of-care to provide
guidance for individualizing opioid drug therapy. Al-
though COP may be used by prescribers for dosage
regimen analysis, design, and modification, caution
should be exercised when applying COP results.
The large between–individual patient variability in re-
sponses to opioid drug administration suggests that
COP will not work accurately in all cases. Uncer-
tainty in patient opioid dosage histories and compli-
ance with opioid dosage regimens makes all efforts
at opioid dosage regimen analysis tentative at best.
Moreover, the expected variability and occasional
errors in the laboratory may confound proper in-
terpretation. These sources of variability underscore
the importance of using COP in conjunction with a
comprehensive patient evaluation and management
approach. This includes careful attention to correct
diagnosis; identification of therapeutic goals and
objective therapeutic end points; correct choice of
pain relievers; constant assessment and reassessment
of therapeutic outcomes; and, when appropriate,
measurement of urine drug levels for therapeutic
drug monitoring. Proper interpretation of analyti-
cal data requires not only an understanding of the
circumstancessurroundingacasebutalsoanappreci-
ation of the circumstances under which any data cited
to aid interpretation were produced (48).
CONCLUSION
COP is a novel application of clinical pharmacokinet-
ics to opioid dosing regimen design, evaluation, and
modification. COP is a quantitative clinical-decision
support tool providing guidance for individualizing
opioid drug therapy at the point-of-care. Application
of COP may prevent iatrogenic overdoses of opioids
and it may reduce prescription costs by allowing pa-
tient dosing regimens to be individualized. Finally,
COP may be useful in drug abuse prevention and de-
tection (DAPD), when it is used in conjunction with
a program of quantitative urine drug monitoring, as it
can allow quantification of expected urine excretion
of administered opioids.
FUTURE DIRECTIONS
We are currently developing software for Apple’s iOS
platform for point-of-care COP. We are also working
on pharmacokinetic phenotyping of individual-based
opioid pharmacokinetics and incorporating pharma-
cogenomics information into ke—pharmacokinetics
and pharmacogenomics modeling.
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